Gunderson Dettmer

Shu is a partner in our Strategic Transactions & Licensing Practice.

Shu represents life sciences and technology companies in their most strategic intellectual property, commercial, and data-driven transactions. She also routinely advises investors and acquirers on the intellectual property and commercial considerations of venture capital financings, mergers and acquisitions, and corporate partnering deals.

Shu’s practice is anchored in life sciences, where she advises biotechnology, medical device, and digital health companies on the strategic transactions that drive value across the product lifecycle. This includes in-licensing and out-licensing, co-development and collaborations, NewCo, spin-out, and joint-venture structures with venture incubators and pharma partners, foundational in-licenses from universities and research institutes, and clinical trial, CRO/CDMO, manufacturing, and supply agreements that support clinical development and product commercialization. Her practice also extends to life sciences deals at the intersection of AI and drug discovery, where she advises on collaborations and licensing arrangements that bring together machine learning models, proprietary datasets, software tools, and experimental biology across research, development, and diagnostic applications.

Shu also brings extensive, differentiated experience advising clients across capital-intensive technology sectors—including artificial intelligence and AI infrastructure, semiconductors and advanced hardware, and cleantech and sustainable mobility—where IP strategy, foundational licensing, and complex commercial arrangements with IP core licensors and tool providers, foundries and manufacturers, strategic partners and customers, and research institutes are central to value creation. Across these sectors, Shu counsels venture-backed emerging growth companies on high-stakes strategic transactions with leading U.S. and international corporations, including strategic partnerships, licensing and development agreements, collaborations, spin-offs, and joint ventures.

Drawing on her legal training and professional experiences in the U.S., Europe, and China, Shu brings a deep, practical understanding of the different legal, regulatory, and business landscapes, particularly in China and Singapore, and is uniquely positioned to help clients navigate cross-border transactions and commercialize and protect their innovations across jurisdictions.

Prior to joining Gunderson, Shu served as a legal assistant at the World Intellectual Property Organization (WIPO) in Geneva, Switzerland.

Life Sciences

City Therapeutics in its strategic collaboration and exclusive license agreement with Biogen to develop RNAi-based therapeutics, with a potential deal value of approximately $1 billion plus royalties.
The Foresite Capital-incubated NewCo that became Candid Therapeutics in its in-licensing of the BCMAxCD3 bispecific T-cell engager antibody from Chinese antibody developer EpimAb Biotherapeutics; the in-licensed asset anchored Candid’s platform and led to its acquisition by UCB for approximately $2 billion.
Tarsus Pharmaceuticals in various strategic partnering transactions, including its development and license agreement with LianBio for the rights to TP-03 (XDEMVY) in China, with potential deal value of $200 million plus royalties.
Foresite Labs (an affiliate of Foresite Capital) in its formation of various NewCos for licensing or acquiring assets from Chinese biotech companies.
Amunix, an immuno-oncology company leveraging its proprietary masking technology for T-cell therapies, in its research collaboration and exclusive license with Merck.
An Atomic Labs spin-out developing ARA-acid-based medical food and drug candidates in its sponsored research agreement and exclusive patent license with Cold Spring Harbor Laboratory, clinical trial agreements, and material transfer agreements.
An Atomic Labs spin-out developing AI models for healthcare application, in its foundational license and data use agreements with University of Florida.
Archetide Bio, an AI-driven biotech company focusing on drug discovery aimed at peptides and oral formulations, in its CRO/CDMO agreements.
Adge Pharmaceuticals, a clinical stage small molecule company that uses elocalcitol for the treatment of obesity, in its foundational in-license for elocalcitol with Roche and its out-license agreement with Elanco.
Biomap, a China-based AI-driven biotechnology company focused on novel drug discovery and precision medicine, in its R&D collaboration with the Mohamed bin Zayed University of Artificial Intelligence (MBZUAI).
Osel, a biotechnology company developing and commercializing a broad portfolio of live biotherapeutic products, in its various licensing, commercial and strategic transactions, including clinical trial agreement with Aarhus University (Denmark), product license and distribution agreement with Miyarisan (Japan), and intragroup collaboration and cross-licensing arrangement.
Countable Labs (fka Enumerix), a precision-genomics PCR instrumentation company, in its manufacturing, supplier, sales, and rental arrangements.
Telesis Bio, developer of high-throughput DNA synthesis technology, in its development and collaboration agreement with an antibody company for automated on-premises genetic materials synthesis leveraging its proprietary Gibson SOLA^®platform.
Liquid Instruments, a FPGA-based test and measurement instrumentation company, in its various vendor and customer agreements.
Various portfolio companies in the NeuroTechnology Investors (NTI) network, including Radical Catheter Technologies and EndoVia.
Shenzhen Eureka Biotechnology, in its foundational cell line in-license from Stanford University.
A diagnostics company in its foundational exclusive patent in-license from Johns Hopkins University.
A medical imaging device company in its foundational exclusive in-license from Washington University.
A Series A mRNA oncology therapeutics company in its Other Transaction Authority (OTA) agreement with ARPA-H and related university subcontracts.
A Series C wearable nerve-stimulation medical device company on its patient, kit-loaner, clinical representative, and claim-processing services agreements.
Represented Benchling, the leading cloud-based R&D platform for life science companies, in its customer agreements with Amgen, Bristol Myers Squibb, Eli Lilly, Regeneron, Genentech, and Zymergen, and its multiple rounds of venture financing through its $106 million Series F.
Represented HumanFirst, a clinical-research data and evidence platform, in its customer agreements with AbbVie, Johnson & Johnson, Roche, Genentech, and Regeneron, and its acquisition by ICON.

Life Sciences

City Therapeutics in its strategic collaboration and exclusive license agreement with Biogen to develop RNAi-based therapeutics, with a potential deal value of approximately $1 billion plus royalties.
The Foresite Capital-incubated NewCo that became Candid Therapeutics in its in-licensing of the BCMAxCD3 bispecific T-cell engager antibody from Chinese antibody developer EpimAb Biotherapeutics; the in-licensed asset anchored Candid’s platform and led to its acquisition by UCB for approximately $2 billion.
Tarsus Pharmaceuticals in various strategic partnering transactions, including its development and license agreement with LianBio for the rights to TP-03 (XDEMVY) in China, with potential deal value of $200 million plus royalties.
Foresite Labs (an affiliate of Foresite Capital) in its formation of various NewCos for licensing or acquiring assets from Chinese biotech companies.
Amunix, an immuno-oncology company leveraging its proprietary masking technology for T-cell therapies, in its research collaboration and exclusive license with Merck.
An Atomic Labs spin-out developing ARA-acid-based medical food and drug candidates in its sponsored research agreement and exclusive patent license with Cold Spring Harbor Laboratory, clinical trial agreements, and material transfer agreements.
An Atomic Labs spin-out developing AI models for healthcare application, in its foundational license and data use agreements with University of Florida.
Archetide Bio, an AI-driven biotech company focusing on drug discovery aimed at peptides and oral formulations, in its CRO/CDMO agreements.
Adge Pharmaceuticals, a clinical stage small molecule company that uses elocalcitol for the treatment of obesity, in its foundational in-license for elocalcitol with Roche and its out-license agreement with Elanco.
Biomap, a China-based AI-driven biotechnology company focused on novel drug discovery and precision medicine, in its R&D collaboration with the Mohamed bin Zayed University of Artificial Intelligence (MBZUAI).
Osel, a biotechnology company developing and commercializing a broad portfolio of live biotherapeutic products, in its various licensing, commercial and strategic transactions, including clinical trial agreement with Aarhus University (Denmark), product license and distribution agreement with Miyarisan (Japan), and intragroup collaboration and cross-licensing arrangement.
Countable Labs (fka Enumerix), a precision-genomics PCR instrumentation company, in its manufacturing, supplier, sales, and rental arrangements.
Telesis Bio, developer of high-throughput DNA synthesis technology, in its development and collaboration agreement with an antibody company for automated on-premises genetic materials synthesis leveraging its proprietary Gibson SOLA^®platform.
Liquid Instruments, a FPGA-based test and measurement instrumentation company, in its various vendor and customer agreements.
Various portfolio companies in the NeuroTechnology Investors (NTI) network, including Radical Catheter Technologies and EndoVia.
Shenzhen Eureka Biotechnology, in its foundational cell line in-license from Stanford University.
A diagnostics company in its foundational exclusive patent in-license from Johns Hopkins University.
A medical imaging device company in its foundational exclusive in-license from Washington University.
A Series A mRNA oncology therapeutics company in its Other Transaction Authority (OTA) agreement with ARPA-H and related university subcontracts.
A Series C wearable nerve-stimulation medical device company on its patient, kit-loaner, clinical representative, and claim-processing services agreements.
Represented Benchling, the leading cloud-based R&D platform for life science companies, in its customer agreements with Amgen, Bristol Myers Squibb, Eli Lilly, Regeneron, Genentech, and Zymergen, and its multiple rounds of venture financing through its $106 million Series F.
Represented HumanFirst, a clinical-research data and evidence platform, in its customer agreements with AbbVie, Johnson & Johnson, Roche, Genentech, and Regeneron, and its acquisition by ICON.

Webinar

Coding with Generative AI: Latest Developments and Practical Risk Management

As part of Gunderson Dettmer's Generative AI Webinar Series, Strategic Transactions and Licensing partner Aaron Fiske and senior associate Shu Hu host a webinar on the latest in generative AI coding tools and their impact on software development. Aaron and Shu discuss legal diligence and representations and warranties tailored for generative AI in venture financing and M&A deals, as well as provide practical steps to manage legal, business, and security risks when using AI coding tools.